Most Read Articles
Pank Jit Sin, 2 years ago
Diagnosis and treatment of NAFLD isn’t always precise, but new developments are helping to pave the way for better management of the disease, shares a panel of experts. 
3 years ago
Treatment with low-dose on-demand hepatitis B immunoglobulin added to entecavir led to decreased hepatitis B virus (HBV) recurrence rate without development of resistance following liver transplantation, according to an assessment of a pilot study.
one year ago
Sanofi’s approach in providing medical education has evolved over the years, by not only limiting the content to disease management and patient outcomes, but also taking into consideration of the various challenges faced by doctors across the different sectors. 
3 years ago

Excerpted from a speech by Datuk Seri Dr. S. Subramaniam, Minister of Health, at the launch of the new palliative care symbol and palliative care photography exhibition by Hospis Malaysia, Kuala Lumpur, 25 April

AIT improves mortality, recurrence in HCC patients after curative treatment

2 months ago

Adjuvant adoptive immunotherapy (AIT) for hepatocellular carcinoma (HCC) patients who have received therapy is both safe and effective for improving mortality rates and tumour recurrence, a new meta-analysis shows.

The Cochrane Library, Scopus, EMBASE and PubMed were searched for studies that investigated the effects of adjuvant AIT on HCC patients after curative treatments compared with either no interventions or control interventions. Those that considered advanced, unresectable or recurrent HCC were excluded.

The Newcastle-Ottawa and the Jadad scales were used to assess the quality of the non-randomized and observational trials, and randomized trials, respectively.

After applying the inclusion and exclusion criteria, eight studies (seven randomized controlled trials [RCT], one cohort study), corresponding to 949 treated and 912 untreated individuals, were included. Four of the RCTs had high methodological quality while three had low scores. The cohort study had a low risk of bias.

A fixed-effects model showed that, compared with curative therapies alone, adjuvant AIT was associated with improved mortality rates at 1 year (risk ratio [RR], 0.63; 95 percent CI, 0.50 to 0.78; p<0.001), 2 years (RR, 0.72; 0.63 to 0.83; p<0.001), 3 years (RR, 0.74; 0.65 to 0.83; p<0.001) and 5 years (RR, 0.88; 0.80 to 0.96; p=0.005).

Similarly, adjuvant AIT was associated with improvements in tumour recurrence rates at 1 year (RR, 0.80; 0.71 to 0.90; p=0.001), 2 years (RR, 0.80; 0.70 to 0.83; p<0.001), 3 years (RR, 0.86; 0.80 to 0.90; p<0.001) and 5 years (RR, 0.91; 0.85 to 0.97; p=0.004).

Finally, no serious adverse events or deaths were documented across the eight studies included. The most common adverse events were chills and fever. Tachycardia, itching, dizziness, myalgia, fatigue, nausea and headaches were also observed.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pank Jit Sin, 2 years ago
Diagnosis and treatment of NAFLD isn’t always precise, but new developments are helping to pave the way for better management of the disease, shares a panel of experts. 
3 years ago
Treatment with low-dose on-demand hepatitis B immunoglobulin added to entecavir led to decreased hepatitis B virus (HBV) recurrence rate without development of resistance following liver transplantation, according to an assessment of a pilot study.
one year ago
Sanofi’s approach in providing medical education has evolved over the years, by not only limiting the content to disease management and patient outcomes, but also taking into consideration of the various challenges faced by doctors across the different sectors. 
3 years ago

Excerpted from a speech by Datuk Seri Dr. S. Subramaniam, Minister of Health, at the launch of the new palliative care symbol and palliative care photography exhibition by Hospis Malaysia, Kuala Lumpur, 25 April